Lower-risk myelodysplastic syndromes treated with Reblozyl, luspatercept – Real-world outcomes
Sudipto Mukherjee from Cleveland Clinic in Ohio presents in this MEDtalk the results of a retrospective, observational cohort study of adults diagnosed with lower-risk myelodysplastic syndromes and treated with luspatercept.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
